Switch theme
Sign up to access all valuation multiples
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
1990
374
LTM Revenue $596M
LTM EBITDA $133M
$381M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kamada has a last 12-month revenue (LTM) of $596M and a last 12-month EBITDA of $133M.
In the most recent fiscal year, Kamada achieved revenue of $48.1M and an EBITDA of $8.3M.
Kamada expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kamada valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $596M | XXX | $48.1M | XXX | XXX | XXX |
| Gross Profit | $266M | XXX | $20.9M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $133M | XXX | $8.3M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 17% | XXX | XXX | XXX |
| EBIT | $81.2M | XXX | $6.0M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $61.3M | XXX | $4.3M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Kamada's stock price is ILS 26 (or $8).
Kamada has current market cap of ILS 1.5B (or $446M), and EV of ILS 1.3B (or $381M).
See Kamada trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $381M | $446M | XXX | XXX | XXX | XXX | $0.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Kamada has market cap of $446M and EV of $381M.
Kamada's trades at 7.9x EV/Revenue multiple, and 45.9x EV/EBITDA.
Equity research analysts estimate Kamada's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kamada has a P/E ratio of 24.4x.
See valuation multiples for Kamada and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $446M | XXX | $446M | XXX | XXX | XXX |
| EV (current) | $381M | XXX | $381M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 7.9x | XXX | XXX | XXX |
| EV/EBITDA | 9.6x | XXX | 45.9x | XXX | XXX | XXX |
| EV/EBIT | 15.7x | XXX | 63.6x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.4x | XXX | 103.2x | XXX | XXX | XXX |
| EV/FCF | 10.1x | XXX | 34.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKamada's last 12 month revenue growth is 7%
Kamada's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $40K for the same period.
Kamada's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kamada's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kamada and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 103% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 151% | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $40K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kamada acquired XXX companies to date.
Last acquisition by Kamada was XXXXXXXX, XXXXX XXXXX XXXXXX . Kamada acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kamada founded? | Kamada was founded in 1990. |
| Where is Kamada headquartered? | Kamada is headquartered in Israel. |
| How many employees does Kamada have? | As of today, Kamada has 374 employees. |
| Who is the CEO of Kamada? | Kamada's CEO is Mr. Amir London. |
| Is Kamada publicy listed? | Yes, Kamada is a public company listed on TAE. |
| What is the stock symbol of Kamada? | Kamada trades under KMDA ticker. |
| When did Kamada go public? | Kamada went public in 2005. |
| Who are competitors of Kamada? | Similar companies to Kamada include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Kamada? | Kamada's current market cap is $446M |
| What is the current revenue of Kamada? | Kamada's last 12 months revenue is $596M. |
| What is the current revenue growth of Kamada? | Kamada revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Kamada? | Current revenue multiple of Kamada is 2.1x. |
| Is Kamada profitable? | Yes, Kamada is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kamada? | Kamada's last 12 months EBITDA is $133M. |
| What is Kamada's EBITDA margin? | Kamada's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of Kamada? | Current EBITDA multiple of Kamada is 9.6x. |
| What is the current FCF of Kamada? | Kamada's last 12 months FCF is $126M. |
| What is Kamada's FCF margin? | Kamada's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Kamada? | Current FCF multiple of Kamada is 10.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
